Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model

Thoracic Cancer

Volumn 3, Issue 3, 2012, Pages 229-238

  Ning, Tao ^a   Jiang, Ming ^a   Peng, Qian ^a   Yan, Xi ^a   Lu, Ze Jun ^a   Peng, Yu Lan ^a   Wang, He Lan ^a   Lei, Na ^a   Zhang, Hui ^a   Lin, Hong jun ^a   Li, Mei ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Endostatin; Normalize; Tumor vasculature

Indexed keywords

EVANS BLUE; PACLITAXEL; RECOMBINANT ENDOSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG CANCER; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

EID: 84864781093     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2012.00111.x     Document Type: Article

References (32)

1. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18.
2. Hashizume H, Falcon BL, Kuroda T etal. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70: 2213-23.
3. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res 2009; 69: 3727-30.
4. Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer 2010; 126: 1777-87.
5. Damia G, D'Incalci M. Contemporary pre-clinical development of anticancer agents - what are the optimal preclinical models? Eur J Cancer 2009; 45: 2768-81.
6. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005; 23: 1295-311.
7. Welch S, Spithoff K, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010; 21: 1152-62.
8. Ning T, Yan X, Lu ZJ etal. Gene therapy with the angiogenesis inhibitor endostatin in an orthotopic lung cancer murine model. Hum Gene Ther 2009; 20: 103-11.
9. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
10. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008; 14: 1540-9.
11. Cerniglia GJ, Pore N, Tsai JH etal. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS ONE 2009; 4: 1-11.
12. Myers AL, Williams RF, Ng CY, Hartwich JE, Davidoff AM. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg 2010; 45: 1080-5.
13. Jain RK. A new target for tumor therapy. N Engl J Med 2009; 360: 2669-71.
14. De Bock KD, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 2011; 21: 73-9.
15. Jiang XD, Dai P, Wu J, Song DA, Yu JM. Inhibitory effect of radiotherapy combined with weekly recombinant human endostatin on the human pulmonary adenocarcinoma A549 xenografts in nude mice. Lung Cancer 2011; 72: 165-71.
16. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res 2010; 136: 1201-11.
17. Wen QL, Meng MB, Yang B etal. Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 2009; 100: 1510-19.
18. Kerbel RS, Emmenegger U, Man S, Munoz R, Folkins C, Shaked Y. Metronomic low-dose antiangiogenic chemotherapy in mice and man. Nat Rev Cancer 2004; 4: 423-36.
19. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 2004; 22: 1198.
20. Reck M, von Pawel J, Zatloukal P etal. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
21. Inai T, Mancuso M, Hashizume H etal. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35-52.
22. Quaia, E. Assessment of tissue perfusion by contrast-enhanced ultrasound. Eur Radiol 2011; 21: 604-15.
23. Kim SC, Yu J, Lee JW, Park ES, Chi SC. Sensitive HPLC method for quantitation of paclitaxel (Genexol) in biological samples with application to preclinical pharmacokinetics and biodistribution. J Pharmaceut Biomed Anal 2005; 39: 170-6.
24. Dickson PV, Hamner JB, Sims TL etal. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-50.
25. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-11.
26. Read TA, Farhadi M, Bjerkvig R etal. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 2001; 61: 6830-7.
27. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91:1071-121.
28. Wildiers H, Guetens G, De Boeck G etal. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-II. Br J Cancer 2003; 88: 1979-86.
29. Bhattacharya A, Seshadri M, Oven SD, Tóth K, Vaughan MM, Rustum YM. Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 2008; 14: 3926-32.
30. Yang JC, Haworth L, Sherry RM etal. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
31. Cobleigh MA, Langmuir VK, Sledge GW etal. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (Suppl.): 117-24.
32. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-6.